Cost-Effectiveness Analysis

Economic evaluation of healthcare programs seeks to compare treatments and preventive measures in terms of their efficiency, that is, their ability to generate health and well-being relative to the costs incurred. This chapter provides an introduction to one particular but widely used evaluation technique: cost-effectiveness analysis (CEA). We present the main conceptual elements of a CEA, measurement techniques that are used, and the challenges and limitations, and we discuss the final interpretation of results within the context of the mental health field.

[1]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[2]  Philippe Beutels,et al.  Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  S. Morris,et al.  Cost of depression among adults in England in 2000. , 2003, The British journal of psychiatry : the journal of mental science.

[4]  S. Frangou,et al.  Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder , 2005, Psychiatry Research.

[5]  G. Alexopoulos,et al.  Cornell scale for depression in dementia , 1988, Biological Psychiatry.

[6]  J. Shearer,et al.  Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches , 2016, PharmacoEconomics.

[7]  N. Devlin,et al.  The Influence of Cost-Effectiveness and Other Factors on NICE Decisions , 2010, Health economics.

[8]  D. Razzouk,et al.  Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study , 2011, Current medical research and opinion.

[9]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[10]  J. Suvisaari,et al.  Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders , 2010, British Journal of Psychiatry.

[11]  Sandra Hollinghurst,et al.  Cost-effectiveness of therapist-delivered online cognitive–behavioural therapy for depression: randomised controlled trial , 2010, British Journal of Psychiatry.

[12]  J. Sekhon,et al.  Advancing quantitative methods for the evaluation of complex interventions , 2016 .

[13]  M. Nordentoft,et al.  Cost-effectiveness of early intervention in first-episode psychosis: economic evaluation of a randomised controlled trial (the OPUS study) , 2013, British Journal of Psychiatry.

[14]  C. Easton,et al.  The cost-effectiveness of four treatments for marijuana dependence. , 2007, Addiction.

[15]  A S Detsky,et al.  Primer on Medical Decision Analysis: Part 1—Getting Started , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  John Brazier,et al.  How Valid and Responsive Are Generic Health Status Measures, such as EQ-5D and SF-36, in Schizophrenia? A Systematic Review , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  E. Wilson.  A Practical Guide to Value of Information Analysis , 2015, PharmacoEconomics.

[18]  M. Barkham,et al.  Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D , 2014, British Journal of Psychiatry.

[19]  Li-ying Kang,et al.  [Solitary median maxillary central incisor syndrome:a case of report]. , 2014, Shanghai kou qiang yi xue = Shanghai journal of stomatology.

[20]  A T McLellan,et al.  An Improved Diagnostic Evaluation Instrument for Substance Abuse Patients: The Addiction Severity Index , 1980, The Journal of nervous and mental disease.

[21]  Christy K. Scott,et al.  Cost-effectiveness analysis of Recovery Management Checkups (RMC) for adults with chronic substance use disorders: evidence from a 4-year randomized trial. , 2013, Addiction.

[22]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[23]  Filip Smit,et al.  Reducing Suicidal Ideation: Cost-Effectiveness Analysis of a Randomized Controlled Trial of Unguided Web-Based Self-help , 2012, Journal of medical Internet research.

[24]  Henry Brodaty,et al.  Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial , 2009, The Lancet Neurology.

[25]  M. Nordentoft,et al.  Does the EQ-5D measure quality of life in schizophrenia? , 2011, The journal of mental health policy and economics.

[26]  D. Moher,et al.  Improving the reporting of pragmatic trials: an extension of the CONSORT statement , 2008, BMJ : British Medical Journal.

[27]  Adam Oliver,et al.  A normative perspective on discounting health outcomes , 2013, Journal of health services research & policy.

[28]  R. Snaith,et al.  The Hospital Anxiety and Depression Scale , 1983 .

[29]  R. P. Bentall,et al.  Effectiveness of group body psychotherapy for negative symptoms of schizophrenia: multicentre randomised controlled trial , 2016, British Journal of Psychiatry.

[30]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[31]  P. Knekt,et al.  The cost-effectiveness of short-term and long-term psychotherapy in the treatment of depressive and anxiety disorders during a 5-year follow-up. , 2016, Journal of affective disorders.

[32]  Martin Knapp,et al.  Maintenance cognitive stimulation therapy: an economic evaluation within a randomized controlled trial. , 2015, Journal of the American Medical Directors Association.

[33]  Jing Jing Li,et al.  Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. , 2009, JAMA.

[34]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[35]  E. Schokkaert.  HOW TO INTRODUCE MORE (OR BETTER) ETHICAL ARGUMENTS IN HTA? , 2015, International Journal of Technology Assessment in Health Care.

[36]  J. Cohen-Mansfield,et al.  Measurement of inappropriate behavior associated with dementia. , 1999, Journal of gerontological nursing.

[37]  D. Goldberg,et al.  A scaled version of the General Health Questionnaire , 1979, Psychological Medicine.

[38]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[39]  J. Lieberman,et al.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. , 2003, Schizophrenia bulletin.

[40]  A. Rothberg.  Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2008 .

[41]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[42]  J. Luyten,et al.  Costing Infectious Disease Outbreaks for Economic Evaluation , 2012, PharmacoEconomics.

[43]  M. Orrell,et al.  Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. , 2013, Health technology assessment.

[44]  S. Iliffe,et al.  Cost‐effectiveness of exercise as a therapy for behavioural and psychological symptoms of dementia within the EVIDEM‐E randomised controlled trial , 2016, International journal of geriatric psychiatry.

[45]  T. Wykes,et al.  Clinical effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial. , 2016, Health technology assessment.

[46]  J. Lieberman,et al.  CATIE and CUtLASS: can we handle the truth? , 2008, British Journal of Psychiatry.

[47]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[48]  M. Orrell,et al.  REMCARE: reminiscence groups for people with dementia and their family caregivers - effectiveness and cost-effectiveness pragmatic multicentre randomised trial. , 2012, Health Technology Assessment.

[49]  Peter B. Jones,et al.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.

[50]  Stavros Petrou,et al.  Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting , 2011, BMJ : British Medical Journal.

[51]  H. Naci,et al.  Economic evaluation of mental health interventions: an introduction to cost-utility analysis , 2016, Evidence-Based Mental Health.

[52]  J. Brazier.  Is the EQ–5D fit for purpose in mental health? , 2010, British Journal of Psychiatry.

[53]  N. Tarrier,et al.  Treatment and prevention of depression after surgery for hip fracture in older people: cost-effectiveness analysis. , 2011, Journal of affective disorders.

[54]  Glyn Lewis,et al.  Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial , 2015, The Lancet.

[55]  Laura E. Gibbons,et al.  Assessing Quality of Life in Older Adults With Cognitive Impairment , 2002, Psychosomatic medicine.

[56]  Willem Kuyken,et al.  Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. , 2008, Journal of consulting and clinical psychology.

[57]  Martin Knapp,et al.  Individual cognitive stimulation therapy for dementia: a clinical effectiveness and cost-effectiveness pragmatic, multicentre, randomised controlled trial. , 2015, Health technology assessment.

[58]  B. Everitt,et al.  Cognitive remediation therapy in schizophrenia: Cost-effectiveness analysis , 2010, Schizophrenia Research.

[59]  A E Ades,et al.  Expected Value of Sample Information Calculations in Medical Decision Modeling , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.